Bladder Cancer Breakthrough: No 90-Day Deaths!

Big news for advanced bladder cancer: a combo of enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) before surgery led to zero 90-day deaths and a whopping 60% complete response rate in a recent study. Even patients who couldn’t get cisplatin saw great results. Plus, survival rates with this treatment are way better than standard chemo. Feels like a game-changer for urothelial cancer! #BladderCancer #CancerResearch #MedicalBreakthrough #UrothelialCancer #Oncology #Health